85 filings
Page 3 of 5
6-K
p924f d1injs
9 May 18
Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development
6:00am
6-K
tpgyw p6o5
19 Apr 18
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018
12:00am
6-K
4j4mzpl
17 Apr 18
Posting of UK Annual Report and Accounts & Notice of AGM
12:00am
6-K
5vrmw 7h56
10 Apr 18
Motif Bio Reports Fiscal Year 2017 Results
12:00am
6-K
7twrcnrfzm7nt sa
3 Apr 18
Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update
12:00am
6-K/A
mj1d9 43hveo5ig
20 Mar 18
Motif Bio Update on NDA Submission for Iclaprim
12:00am
6-K
p0h1q8 m2qq
20 Mar 18
Motif Bio Update on NDA Submission for Iclaprim
12:00am
6-K
9lggsnmqbnqwl1i
19 Mar 18
Motif Bio to present at upcoming investor and scientific conferences
12:00am
6-K
g1k44lk6
1 Mar 18
Current report (foreign)
12:00am
6-K
01o7ysan4ak9
21 Feb 18
Motif Bio to Present Iclaprim Data at ECCMID 2018
12:00am
6-K
fikxs5njlm i3e7
5 Feb 18
Appointment of Jonathan E. Gold as Interim Chief Financial Officer
12:00am
6-K
3htm6qc
19 Jan 18
Motif Bio Announces Filing of U.S. Shelf Registration
12:00am
6-K
8ojue4 7c3
5 Jan 18
Motif Bio to participate in panel discussion at upcoming Cantor Antibiotics Summit
12:00am
6-K
9zavr2hrvppd1dymh
22 Dec 17
Motif Bio notes statement from Amphion Innovations
12:00am
6-K
lbkx1 ok70
21 Dec 17
Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious Diseases
12:00am
6-K
4s8fkyqw
14 Dec 17
Current report (foreign)
12:00am
6-K
j7fwt6 hcc822oib
15 Nov 17
Current report (foreign)
12:00am
6-K
6pj3 5dgs
6 Oct 17
1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Fibrosis Patients
12:00am
6-K
ytdmwe8si
4 Oct 17
Current report (foreign)
12:00am
6-K
jtx2hrrcdhduf
29 Sep 17
Current report (foreign)
12:00am